BioNTech (BNTX) news
Recent news
Biontech ADRs plunge 11%, most intraday since March 10
AInvest Wire · 3d agoBiontech falls 6% in US premarket on trial termination
BioNTech SE (BNTX) shares fell 6% in U.S. premarket trading on August 28, 2026, following the termination of a clinical trial for one of its oncology candidates. The decline came amid ongoing investor caution around the company’s pipeline and valuation, particularly after a recent 22% rally driven…
AInvest Wire · 3d agoBiontech SE: Biontech: Terminates phase 2 clinical trial of Autogene Cevumeran in colorectal cancer
Biontech SE has announced the termination of its phase 2 clinical trial for Autogene Cevumeran, an individualized cancer immunotherapy being developed for the treatment of colorectal cancer. The decision follows a review of interim data and strategic considerations regarding the development pathway…
AInvest Wire · 3d agoDuality Bio: Research, collaboration, license pact w/ Genentech
Duality Biologics, a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics, has entered into multiple strategic agreements in recent years to expand its ADC portfolio and strengthen its industry position. In April 2023,…
AInvest Wire · 3d agoPfizer and BioNTech receive U.S. FDA approval for XFG-adapted COVID-19 vaccine
AInvest Wire · 3d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.